| 主权项 |
1. A method for determining whether a subject having relapsing-remitting multiple sclerosis (RRMS) is undergoing relapse of the disease, comprising
(i) determining mRNA expression levels for one or more biomarkers selected from the group consisting of SIRT1, RGC-32, FasL and IL-21 in a population of cells, (ii) determining mRNA expression levels for L13 in the same population of cells, and (iii) calculating a ratio of biomarker mRNA expression to L13 mRNA expression, wherein when the biomarker is SIRT1 and the SIRT1/L13 ratio is <3.06±10%, the subject is determined to be undergoing relapse, wherein when the biomarker is RGC-32 and the RGC-32/L13 ratio is <1.27±10%, the subject is determined to be undergoing relapse, wherein when the biomarker is FasL and the FasL/L13 ratio is <52.6±10%, the subject is determined to be undergoing relapse, and wherein when the biomarker is IL-21 and the IL-21/L13 ratio is >16.9±10%, the subject is determined to be undergoing relapse. |
